Provention Builds On J&J Disease Interception Model

Founded earlier in 2017 with a plan of making quick "go/no-go" development decisions based on objective data, Provention taps into Johnson & Johnson for a pair of IBD candidates.

businessman and businesswoman are shaking hands and exchanging folder after agreement was reached

Founded earlier this year to develop other firms’ candidates to intercept or prevent immune-mediated diseases, Provention Bio Inc. added its first two clinical candidates – both targeted at inflammatory bowel disease – by licensing a pair of candidates Sept. 21 from Janssen Pharmaceutica NV.

Not coincidentally, Janssen parent Johnson & Johnson is focused on moving beyond traditional treatment of diseases, having launched a Disease Interception Accelerator in February 2015 to predict and preempt...

After New Jersey-based Provention made its debut in April with a $28.4m Series A financing – with participation from the Johnson & Johnson Innovation Fund – it landed its first...

More from Deals

More from Business